Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-304: tarlatamab versus topotecan in relapsed small cell lung cancer after first-line platinum therapy
MOH_2023-10-10_012987Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Started May 2023; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2023-10-10_012987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-10_012987.